Targeted delivery strategies for DNA and viral therapeutics using a range of novel strategies, the improvement of the long term stability of biopharmaceuticals by lyophilisation and new affinity methods for their purification.
The Bioscience Engineering Group (BSEG), Cambridge University, UK collaborates widely with academia and industry in the UK, Europe and US to develop novel strategies for the manufacture, formulation and delivery of biopharmaceuticals. The emphasis is on highly potent biological medicines and in recent years the group has worked on the primary and secondary processing of mammalian cell culture products, the processing of serum proteins, viral vaccines and DNA gene therapy vectors.
Nigel Slater has developed biosynthetic materials that facilitate the delivery of payloads into cells. This technology mimics the efficient viral transfection within a synthetic polymer framework. In in-vitro cul-tured cells, amphiphilic polymers display endosmolytic behaviour and traffic rapidly to the nucleus. PEGylated doxorubicin-conjugated constructs are toxic in in-vitro tumour cell models and evade efflux mechanisms in multidrug resistant cells.